Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas ...

Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it agreed to a $90 million settlement with Japan's Astellas Pharma ...

Zydus Lifesciences has reached a settlement agreement with Astellas in a patent dispute involving overactive bladder therapy Myrbetriq, which will allow its generic to remain on sale in the US.

Lupin Ltd reported a consolidated net profit of ₹1,175.6 crore in Q3 FY26, up 37.5% year-on-year, though down sequentially ...

Lupin resolves patent dispute with Astellas, agreeing to pay $90 million to continue selling Mirabegron for overactive ...

Mumbai: Pharma major Lupin has announced the completion of a cGMP inspection carried out by the United States Food and Drug ...

In a statement, Japan's Astellas said the specific terms of the settlement were confidential; however, a regulatory filing has revealed that the Indian pharma group has agreed to pay $90 million to ...

Lupin said on Tuesday it agreed to a $90-million settlement with Japan's Astellas Pharma in a patent dispute over the bladder disorder drug Mirabegron, a move that allows it to continue selling the pr ...

The product is indicated for treating an overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary ...

MUMBAI, India, Feb ...

On Friday, a post on the official X (formerly Twitter) account for the Lupin the 3rd franchise announced a new animated movie set to come out next year. The film, tentatively titled Lupin the IIIrd ...